Market research

LBRX LB Pharmaceuticals Inc Common Stock

NASDAQ USD Healthcare

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market facts

P/E ratio: Not available
Analyst target: 53.375
Dividend yield: Not available
Beta: Not available

Loading price history…

Profile

Company facts

Exchange: NASDAQ
Currency: USD
Sector: Healthcare
Industry: Biotechnology
ISIN: US50180M1080
P/E ratio: Not available
Analyst target: 53.375
Dividend yield: Not available
Beta: Not available

About

About LB Pharmaceuticals Inc Common Stock

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Visit company website

Reported results

Fundamentals

Open this section to load reported financial history.

Annual returns

No comments yet

Start a focused discussion about LBRX.

LBRX LB Pharmaceuticals Inc Common Stock

Price & volume

Company facts

About LB Pharmaceuticals Inc Common Stock

Fundamentals

Earnings

Cash flow

Profitability

Valuation

Performance

Annual returns

Investor discussion

No comments yet